U.S. Stock Market Midday Update: Aptorum Group's stock price plummets 12.59%, with no news but active capital flow attracting attention

U.S. Stock Market Midday Update

Aptorum Group fell 12.59%. The stock price of Aptorum Group dropped 12.59%, with no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

Stocks with High Trading Volume in the Industry

Precision Science rose 0.13%. Based on recent key news:

1. On November 20, Abbott announced the acquisition of Precision Science for $105 per share, with a total transaction value of approximately $21 billion. This news drove Precision Science's stock price up by 18%. Source: Zhitong Finance

2. On November 20, William Blair analysts pointed out that Abbott's offer to acquire Precision Science needs to exceed $100 per share, and the market reacted positively to this news, causing Precision Science's stock price to soar by 21%. Source: Zhitong Finance

3. On November 21, Wells Fargo raised the target price for Precision Science from $85 to $105, reflecting the market's optimistic expectations for the acquisition. Source: Zhitong Finance. The cancer diagnostics market is growing rapidly, with significant capital inflow.

AbbVie rose 3.07%. Based on recent key news:

1. On November 19, AbbVie announced that its subcutaneous T-cell bispecific antibody Epkinly, in combination with rituximab and lenalidomide, has been approved by the FDA for the treatment of adult patients with relapsed or refractory follicular lymphoma. This approval expands the indications for Epkinly and boosts market confidence in AbbVie, driving the stock price up.

2. On November 18, AbbVie released a new indication statement for its drug Rinvoq, which has been approved by the FDA for the treatment of inflammatory bowel disease. This news further enhances investors' expectations for AbbVie's future growth potential, promoting an increase in stock price.

3. On November 21, market analysts maintained a rating of "Moderate Buy" for AbbVie, despite other stocks being considered better investment choices. AbbVie's drug approvals and market performance still attract investors' attention. The pharmaceutical industry has performed strongly recently, with FDA approvals boosting stock prices.

Gilead Sciences rose 1.61%. Based on recent key news:

1. On November 19, Gilead Sciences' Chief Commercial Officer Johanna Mercier sold 28,000 shares of the company's common stock for $3,524,173. This insider trading may raise market concerns about the confidence of the company's management, leading to stock price volatility.

2. On November 19, Gilead Sciences announced that Deborah Telman will resign from her position as Executive Vice President on December 5. Executive changes may affect investors' expectations for the company's future strategy, thereby impacting the stock price.

3. On November 19, analysts rated Gilead Sciences' stock as "Outperform," mainly due to the company's strategic progress in its HIV product portfolio and strong financial performance Analysts' positive evaluations have boosted market confidence in the stock. The biopharmaceutical industry has performed strongly recently, with significant capital inflows.

Stocks ranked among the top in industry market capitalization

Amgen rose 1.87%. Based on recent key news:

1. On November 19, Amgen's Imdelltra received full FDA approval for extensive-stage small cell lung cancer. The drug showed significant survival extension effects in clinical trials, driving the stock price up. Source: Reuters

2. On November 20, Amgen's Vice President Grygiel Nancy A submitted an application to sell restricted securities, which may raise market concerns about insider trading. Source: SEC announcement

3. On November 21, analyst Mizuho Securities maintained a hold rating on Amgen, with a target price of $280, and the market's reaction to the rating was relatively muted. Source: TipRanks The biopharmaceutical industry's innovation is accelerating, but risks need to be monitored